Graeme Moyle
About
In The Last Decade
Graeme Moyle
210 papers receiving 6.6k citations
Peers
Comparison fields: 5 of 116
- Infectious Diseases 4.9k
- Virology 3.8k
- Emergency Medicine 2.4k
- Epidemiology 1.5k
- Hepatology 458
Countries citing papers authored by Graeme Moyle
This map shows the geographic impact of Graeme Moyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graeme Moyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graeme Moyle more than expected).
Fields of papers citing papers by Graeme Moyle
This network shows the impact of papers produced by Graeme Moyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graeme Moyle. The network helps show where Graeme Moyle may publish in the future.
Co-authorship network of co-authors of Graeme Moyle
This figure shows the co-authorship network connecting the top 25 collaborators of Graeme Moyle. A scholar is included among the top collaborators of Graeme Moyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Graeme Moyle. Graeme Moyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 15 | |
| 2 | A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients. | 0 |
| 3 | 84 | |
| 4 | 25 | |
| 5 | RDEA806, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, Shows Positive Outcome in Treatment of Näive HIV Patients | 4 |
| 6 | 22 | |
| 7 | Advances in HIV therapeutics: news from the 4th International AIDS Society Conference. | 2 |
| 8 | 11 | |
| 9 | 2 | |
| 10 | The impact of abacavir on lipids and lipodystrophy. | 4 |
| 11 | Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095. | 2 |
| 12 | 14 | |
| 13 | 9 | |
| 14 | Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution. | 13 |
| 15 | 8 | |
| 16 | 7 | |
| 17 | Commentary: resistance testing--a clinical perspective. | 1 |
| 18 | 20 | |
| 19 | 124 | |
| 20 | 8 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.